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DCONCLUSIONS
This study demonstrates that continuous systolic over-
load for ventricle retraining causes hyperactivity in myocar-
dial G6PD, together with RV dilation and dysfunction. That
enzyme hyperactivity may be related to an unbalanced re-
dox determined by a constant and pathologic systolic over-
load. Given that pentose phosphate pathway enhances
cytosolic NADPH availability, this altered energy substrate
metabolism can elevate levels of free radicals by NADPH
oxidase, an important mechanism in the pathophysiology
of heart failure. On the other hand, intermittent systolic
overload has promoted a more efficient RV hypertrophy
than the continuous one, with better preservation of myo-
cardial performance and smaller G6PD activity. Clinical
studies comparing adjustable and traditional pulmonary
trunk banding should be welcomed to translate those find-
ings to the practice of ventricular retraining.
We are grateful to Sachin A. Gupte, MD, PhD, from University
of South Alabama, for his helpful suggestions on the revised
manuscript.
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Dr William J. Brawn (Birmingham, United Kingdom). I have
no disclosures. I have 2 questions.
In the human situation, acutely raising the ventricular ratio to
70% is usually followed by a fall in this ratio, probably with an as-
sociated falling cardiac output. How do you adjust the band, and
how frequently, to maintain that 70% ratio in your animals?
DrAtik.That is a very good point. Thank you for your question.
In our study, we performed the operation, and we have allowed
the heart to recover for 72 hours beforewe initiated training. By the
time we did it, we tightened the band to achieve that ratio. Some-
times we have to loosen it a little bit because there was a drop of
more than 10% in systolic blood pressure or there were arrhyth-
mias or agitation and hypoxia. So we went back to 0.5 or 0.6 ratio
and waited a few minutes and then we tried it again. If it was not
possible, we left the band tightened up to a tolerable point for the
animal. Reassessments were made every 24 hours and in almost all
the animals we had to readjust at that time.
Dr Brawn. Thank you. Final question, have you any insight as
to how long it takes to upregulate the G6PD activity, how acutely it
occurs?
Dr Atik. We do not have an answer for that question. This is
a very good point. Actually, G6PD activity has a 2-fold mecha-
nism. First, it enhances ribose 6-phosphate, which is a precursor
of de novo production of DNA, which is good for hypertrophy.
On the other hand, G6PD may enhance superoxide anion genera-
tion, which is bad for hypertrophy and can induce myocardial in-
jury. Sowe really do not know how long does it take tomodulate its
activity.diovascular Surgery c Volume 142, Number 5 1113
